Deep vein thrombosis future or investigational therapies

Ongoing Research

Phase 3 Trials Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer

• Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
• Secondary Outcome Measures: Bleeding
• Estimated Enrollment: 2,430 patients
• Study Start Date: May 2008
• Estimated Study Completion Date: August 2012